Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH Income Before Tax

Profit after all operating and non-operating items but before income tax.

Accendra Health, Inc.NYSE: ACH

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$16.25M, compared with -$35.07M a year earlier. Trailing-twelve-month income before tax was -$112.8M.

Context

  • Income before tax amounted to 3.7% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Income before tax increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$16.25M or moves back toward the trailing-twelve-month quarterly average of -$28.2M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$16.25M-103.8% QoQ
Last fiscal yearDec 2025
-$101.95M+71.5% YoY
LTMMar 2026
-$112.8M+67.1% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+53.7%——
1 year+71.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(101.95M) USD
Year-over-year change
+71.5%

Income Before Tax vs competitors

How ACH compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +67.1% is the highest of 11, against a peer median of +27.6%.
  • Income before tax amounts to 4.2% of revenue for ACH, versus a peer median of 90.4%.
ACH Competitors
Income Before Tax for ACH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGHTSight Sciences, Inc.LTM Mar 2026-$37.27M USD+24.1%—46.9%
HITIHigh Tide Inc.LTM Apr 2026-CA$45.98M CAD-416.6%—6.8%
CVRXCVRx, Inc.LTM Mar 2026-$52.67M USD-2.2%—89.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M USD+46.5%—832.6%
OMOutset Medical, Inc.LTM Mar 2026-$74.03M USD+34.7%—63.0%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.93M USD-26.6%—871.8%
EDITEditas Medicine, Inc.LTM Mar 2026-$108.95M USD+56.6%—281.6%
ACHAccendra Health, Inc.LTM Mar 2026-$112.8M USD+67.1%—4.2%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$173.76M USD+31.0%——
CABACabaletta Bio, Inc.LTM Mar 2026-$175.43M USD-38.4%——
CGCCanopy Growth CorporationLTM Mar 2026-CA$286.05M CAD+52.1%—91.6%
Peer median (excluding ACH) —+27.6%—90.4%

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.79B9.96B10.33B10.7B2.76B
Cost of Revenue8.27B8.13B8.21B8.48B1.56B
Gross Profit1.51B1.83B2.13B2.22B1.2B
Gross Margin15.5%18.3%20.6%20.7%43.5%
Research & Development12.1M0000
Selling, General & Admin1.08B1.55B1.81B1.91B1.05B
Operating Expenses1.14B1.68B2.02B2.43B1.05B
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
EBITDA415.47M368.45M390.57M51.22M364.68M
EBITDA Margin4.2%3.7%3.8%0.5%13.2%
Operating Income368.47M142.91M104.51M(207.77M)150.16M
Operating Margin3.8%1.4%1.0%-1.9%5.4%
Interest Income00000
Interest Expense48.09M128.89M157.92M143.8M129.2M
Other Income / Expenses(91.72M)(132.02M)(159.23M)(149.59M)(252.11M)
Income Before Tax276.75M10.89M(54.73M)(357.36M)(101.95M)
Pre-Tax Margin2.8%0.1%-0.5%-3.3%-3.7%
Income Tax Expense55.17M(11.5M)(13.43M)5.33M729K
Net Income221.59M22.39M(41.3M)(362.69M)(1.1B)
Net Margin2.3%0.2%-0.4%-3.4%-39.8%
EPS (Basic)3.050.30(0.54)(4.73)(14.31)
EPS (Diluted)2.940.29(0.54)(4.73)(14.31)
Weighted Avg Shares72.74M74.5M75.79M76.74M76.9M
Weighted Avg Shares (Diluted)75.49M76.22M75.79M76.74M76.9M

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.